Abstract-We describe extracellular interactions between fibronectin (Fn) and vascular endothelial growth factor (VEGF) that influence integrin-growth factor receptor crosstalk and cellular responses. In previous work, we found that VEGF bound specifically to fibronectin (Fn) but not vitronectin or collagens.
F ibronectin (Fn) and vascular endothelial growth factor (VEGF or VEGF-A) are key regulators of blood vessel growth. [1] [2] [3] Gene deletion studies have demonstrated that both Fn and VEGF, and their cognate receptors ␣ 5 ␤ 1 and VEGF receptor-2 (VEGFR-2), are critical for vascular development. 4 -9 During vascular growth, endothelial cells (ECs) are recruited into a tightly controlled program of cell activation, gene expression, adhesion, motility, and proliferation. 10, 11 Crosstalk between integrins and growth factor receptors (receptor tyrosine kinases, RTKs) is a key part of this control process. [12] [13] [14] [15] [16] EC responses to growth factors like VEGF are modulated by the outside-in signals conveyed from integrins, reflecting the conditions of the extracellular milieu. Hence, the local mixture of extracellular matrix (ECM) proteins as well as the type and density of integrins expressed by the cell may modulate its responses to growth factors. Integrin engagement by a specific matrix protein can transactivate VEGF receptors, as shown by Groopman and colleagues for fibronectin (Fn) and VEGF receptor-3, via ␣ 5 ␤ 1 , 17 and by Moro et al for epidermal growth factor receptor. 18 Others have shown that ␤ 1 activation by Fn can modulate VEGF responses, 19 and that ␤ 3 activation may increase VEGF production in tumor cells. 20 Conversely, occupancy of VEGFR-2 by VEGF can activate integrins. Byzova et al have shown that VEGF activates both ␣ v ␤ 3 and ␣ 5 ␤ 1 on ECs. 21 Finally, integrins and receptor tyrosine kinases (RTKs) share a number of important signaling molecules, including Src, FAK, and phosphatidylinositol 3-kinase (PI3K). 13 Our previous work has focused on the specificity of interactions between Fn and VEGF, and their cognate receptors, ␣ 5 ␤ 1 and VEGFR-2. 22, 23 We found VEGF bound to Fn and that platelets secreted VEGF/Fn complexes. In the presence of the ligands VEGF and Fn, their corresponding receptors coimmunoprecipitated. Fn, but not vitronectin, induced sustained mitogen-activated protein kinase (MAPK) activation in response to VEGF. Thus we predicted that the VEGFenhancing activities of Fn were attributable, in part, to its binding to VEGF.
This present study was undertaken to more precisely map the binding site(s) for VEGF within the C-terminal regions of Fn and to determine the mechanisms of Fn-induced enhancement of VEGF activity. Using recombinant Fn fragments, and synthetic peptides, we have mapped the VEGF-binding site to the established heparin-II (Hep-II) site of Fn type III modules 13 to 14. 24, 25 This VEGF-binding domain of Fn was found to be necessary but, by itself, was not sufficient for the promotion of VEGF biological activity. Only bivalent Fn constructs encompassing both the ␣ 5 ␤ 1 and VEGF-binding domains significantly promoted endothelial migration, proliferation, and sustained Erk phosphorylation. Purely costimulatory signaling (via occupancy of integrin and VEGFR-2 receptors) was a weaker influence on VEGF activity, because mixtures of VEGF with monovalent Fn fragments containing cell-and VEGF-binding domains showed less migration, proliferation, and no late phase of Erk phosphorylation.
Materials and Methods

Cell Culture
Human umbilical vein ECs (HUVECs) (Cascade Biologics) were maintained in MCDB-131 growth medium (MCDB-131 medium containing 5% FBS, 2 ng/mL basic fibroblast growth factor [bFGF], 10 ng/mL VEGF, and 10 g/mL heparin). HUVECs between passage 3 to 8 were used for experiments.
cDNA Construction
Human Fn cDNA was obtained by RT-PCR using human liver mRNA and sequenced to verify no base changes during PCR amplification. The Fn type III modules were obtained by PCR amplification using Fn cDNA as template. We used the following nomenclature for describing the recombinant Fn constructs: rFnIII 9 -10 indicates recombinant Fn protein encompassing type III repeats 9 to 10; rFnIII 9 -10/12-14 , a single protein encompassing type III repeats 9 to 14, omitting 11. A rFnIII [12] [13] [14] with the heparin-binding sites on FnIII domains 13 and 14 mutated (Arg or Lys3 Ser, termed "gag AC") was obtained as previously described. 26 For details on the construction of the rFn plasmids and their expression and purification, please see the online data supplement, available at http://circres.ahajournals.org.
EC Migration Assay
EC chemotactic migration to VEGF (10 ng/mL; upper chamber) was studied in the presence of different rFn fragments (0.2 mol/L; bottom chamber). Ninety-six well ChemoTx microtiter plates (Neuro Probe Inc) were used, as previously described. 22, 27 Positive and negative controls included native Fn, vitronectin, or albumin all at 10 g/mL, in the place of the tested rFn fragments.
Endothelial Proliferation Assay
Early-passage HUVECs (3000 cells/well) in 96-well plates were cultured in MCDB-131 medium containing fibronectin-depleted FBS (0.25%). Cells were incubated with albumin, VEGF alone (10 ng/mL), or VEGF with native Fn (10 g/mL) or rFn fragments (0.2 mol/L) for 72 hours. Heparin was used at a final concentration of 1 g/mL. Cell growth was determined by using CyQuant reagent (Molecular Probes) according to the instructions of the manufacturer.
Western Blot Analyses
For analysis of Erk phosphorylation, 5ϫ10 5 HUVECs were plated onto 60-cm 2 culture dishes and incubated overnight in MCDB-131 growth medium. Cells were then washed twice and incubated for 4 hours in serum-free MCDB-131 medium. Cells were stimulated with VEGF (10 ng/mL) or VEGF with different Fn combinations. At different time points, cells were lysed and Erk phosphorylation detected as previously described. 28 Signal densities were quantified by the NIH Image program, and the activation of phosphorylated protein was expressed as the fold increase over basal (unstimulated) levels, adjusted for total protein loading, measured from separate blots.
To measure VEGFR-2 phosphorylation, HUVECs (2ϫ10 6 cells) were cultured for 48 hours in MCDB-131 growth medium. Before assay, cultures were washed and replaced with serum-free MCDB-131 containing ITS supplement (BD Bioscience) and incubated for a further 4 hours. Culture plates were then stimulated with a low dose of VEGF (1 ng/mL) in the absence or presence of rFNIII 9 -10/12-14 for 2 minutes at 37°C. Cell lysates were incubated with anti-VEGFR-2 rabbit monoclonal antibodies (Cell Signaling) for 16 hours at 4°C and immune complexes precipitated with protein G sepharose. Protein samples were reduced, separated by Bis-Tris PAGE gels, transferred to polyvinyl difluoride (PVDF) membranes, probed with anti-phospho VEGFR-2 antibodies and signals developed by chemiluminescence. Blots were stripped and reprobed with anti-VEGFR-2.
I-VEGF Solid-Phase Binding Assays
The measurement of direct binding of 125 I-VEGF to Fn fragments was performed as described previously. 22 For peptide competition assays, the same binding assay methods were used, with recombinant C-terminal rFn III 9 -10/12-14 or rFnIII [12] [13] [14] immobilized on the plates.
Surface Plasmon Resonance Analysis
Surface plasmon resonance analysis (SPR) binding experiments were conducted to measure the equilibrium binding parameters between VEGF 165 and native fibronectin or rFnIII 9 -10/12-14 . The detailed methods are described elsewhere. 29 In brief, a 2-channel SPR670M apparatus (Moritex Corp) was used with a running buffer of PBS, 0.05% Tween-20 at a flow rate of 15 L/min at room temperature. The matrix proteins were immobilized on the gold chip using N-hydroxysuccinimidyl coupling, sensograms recorded over a range of VEGF concentrations (25 to 800 nmol/L), and the kinetic binding parameters derived using the software of the manufacturer.
Statistical Analysis
Individual experiments were performed at least in triplicate, and the data presented are the means and SEM of at least 3 to 4 independent experiments, as noted. The Student's t test was used to compare different treatments. Figure 1 illustrates a schematic of the native fibronectin protein and the design of the recombinant fragments. Each protein was expressed and purified to homogeneity, as described in Materials and Methods. A Bis-Tris PAGE gel shows representative samples of the purified proteins.
Results
Expression and Purification of Fibronectin Fragments
VEGF Binding to Recombinant Fn Domains and Competition by Peptides
We first measured the concentration dependence of 125 I-VEGF 165 binding to different immobilized recombinant Fn fragments. These experiments were all conducted in the absence of exogenous heparin, indicating that heparin is not a required cofactor for VEGF/Fn binding. In preliminary experiments, the actual quantity of experimental proteins deposited on the plate was measured by protein assay, confirming that the final density of coating was comparable for all test proteins. As shown in Figure 2 , VEGF bound rFnIII [12] [13] [14] and rFnIII 8 -14 in a concentration-dependent manner. Binding to rFnIII 8 -11 was negligible. In subsequent binding assays, a coating concentration of 0.2 mol/L was used for all proteins. The binding of VEGF to individual rFnIII domains was then evaluated. Figure 3A shows that VEGF does not bind significantly to any of the individual type III domains studied but did bind to all fragments containing FnIII [13] [14] in continuity (ie, native Fn, rFn 8 -14 , rFn [12] [13] [14] . Figure 3A and 3B shows that the linkage of the ␣ 5 ␤ 1 integrin-binding domain with rFnIII [12] [13] [14] (as in the constructs rFnIII 8 -14 or III 9 -10/12-14 ) further enhanced VEGF binding when compared with rFnIII [12] [13] [14] alone. The binding of VEGF to rFnIII 8 -14 and rFnIII 9 -10/12-14 when compared with native Fn was consistently higher, suggesting a higher affinity for these fragments. Surface plasmon resonance binding analysis was used to compare the VEGF affinities of rFnIII 9 -10/12-14 to native Fn. The rFnIII 9 -10/12-14 fragment had a 43% lower dissociation constant (K d , 73.5 versus 129.3 nmol/L), a faster on-rate and a smaller off-rate (supplemental Table I ). Because the region of FnIII 12-14 is known to be an important heparin-binding region, 24, 25, 30 we wanted to determine whether the key heparinbinding residues of FnIII [12] [13] [14] were required for binding 125 I-VEGF was incubated for 2 hours on wells coated with increasing concentrations of rFn fragments. After washing, bound VEGF was eluted with 0.1 mol/L NaOH/1% SDS and radioactivity quantified in a gamma counter. Data are presented as the mean of triplicate determinationsϮSEM.
VEGF. To that end, the construct rFnIII 9 -10/12-14gagAC was prepared, in which the lysines and arginines of repeats 13 and 14 were mutated to serine, as previously described. 26 Figure  3B shows that the loss of these heparin-binding residues completely abolished VEGF binding.
Peptides (listed in the Table) encompassing the native heparin-binding regions in FnIII [13] [14] were also used as soluble competitors of 125 I-VEGF binding to immobilized rFnIII 12-14 or rFnIII 9 -10/12-14 . Two other peptides were also studied: a truncated version containing the putative key heparin-binding site of FnIII 13 , as well as a well-characterized heparin-binding site from the A1 domain of von Willebrand factor (vWf) 31 (Table) . The results of peptide competition against VEGF binding to either rFnIII [12] [13] [14] , or rFnIII 9 -10/12-14 substrates were not significantly different, so the data were pooled. The Table shows their estimated IC 50 (concentration that inhibits VEGF binding by 50%), and Figure 4 shows their inhibition curves. The most potent peptide was a heparin-binding region in FnIII 14 (core motif is PRAR). Second and third in rank order were the heparin-binding peptides derived from FnIII 13 (core motif PRRAR) and FnIII 14 (IYVIALKNNQKSEPLI-GRKKT), respectively. Truncating the heparin-binding domain of FnIII 13 eliminated its ability to compete with the immobilized Fn fragment for binding VEGF. Figure 4B correlates the potency of each peptide competitor with its total number of basic residues. The peptide charge accounts for some, but not all, of the apparent affinity of the peptides for VEGF. The most potent Fn peptide bears the same net charge as the vWf heparin-binding peptide but has an IC 50 that is 600 times lower. The other 2 Fn peptides that share the PRRAR or PRAR motif possess the same number of heparinbinding residues but differ in affinity by 3.5-fold.
Specificity of Fn Domains That Promote VEGF-Mediated EC Cell Migration and Proliferation
We hypothesized that the formation of a unique extracellular VEGF/Fn complex promotes VEGF biological activity, mediated in part by the bivalent capacity of Fn to simultaneously bind ␣ 5 ␤ 1 and VEGF. Accordingly, we measured the migration and proliferation of HUVECs in response to VEGF, in the presence of different native and recombinant matrix proteins. Figure 5A shows that there was minimal cellular migration toward VEGF in the absence of a matrix component, or with the addition of rFnIII [12] [13] [14] alone. Most of the proteins containing an integrin-binding domain (eg, vitronectin, rFn 9 -10 , and rFn 9 -10/12-14gagAC ) supported some migration to VEGF. In contrast, all bivalent matrices encompassing both the ␣ 5 ␤ 1 and the VEGF-binding domains (FnIII 8 -14 and FnIII 9 -10/12-14 ) increased cell migration by 2-to 3-fold. To distinguish between simple costimulatory signaling through the independent ligands (ie, integrin and growth factor receptor), chemotactic migration to VEGF was also measured in the presence of equivalent concentrations of a mixture of the isolated domains of rFnIII 9 -10 and rFnIII [12] [13] [14] . This mixture did support a modicum of cell migration above baseline but did not increase migration to the extent induced by a bivalent Fn construct that linked both those domains.
We next examined whether rFn fragments promoted VEGF-induced HUVEC proliferation. As shown in Figure  5B , the extent of HUVEC growth in response to VEGF was enhanced in the presence of native Fn or rFnIII 9 -10/12-14 , compared with the cell or VEGF-binding domains alone (rFnIII 9 -10 or rFnIII [12] [13] [14] I-VEGF was incubated for 2 hours on wells coated with either individual or continuous rFn type III domains (0.2 mol/L) (A) or wells coated with rFn molecules encompassing both the integrin (9 to 10) and heparin-binding domains (12 to 14) (B). GagAC denotes mutation of the heparin-binding domains on type III module 13 and 14. After washing, bound VEGF was eluted with 0.1 mol/L NaOH/1% SDS and radioactivity quantified in a gamma counter. Data are the meansϮSEM of 3 to 4 independent experiments performed in triplicate. Dotted lines are 95% confidence intervals for control binding to albumin.
(at the same concentrations, 10 g/mL) showed less increase in proliferation compared with the divalent fragment.
Modulation of VEGF-Mediated Signaling by Specific rFn Domains
Previously, our laboratory reported that VEGF/Fn complexes prolonged cell signaling induced by VEGF alone, 22 suggesting that such extracellular complexes may influence the magnitude and duration of cell signaling. Therefore, we examined the time course and sensitivity of Erk signaling to VEGF and different Fn domains. As shown in Figure 6 , VEGF combined with native Fn produced a higher early (5 minutes) peak in phosphorylation, as well as more sustained activation at 1.5 to 3 hours. In comparison with native Fn, the rFnIII 9 -10/12-14 induced an even higher early peak and a second peak of Erk activation at approximately 1.5 hour. A mixture of rFnIII 9 -10 and rFnIII [12] [13] [14] (at the same individual concentrations as other fragments tested) did not induce any late Erk activation. When tested individually, the cell binding (rFnIII 9 -10 ) or VEGF-binding domains (rFnIII [12] [13] [14] did not induce any late Erk activation. The divalent recombinant Fn fragment rFnIII 9 -10/12-14 , significantly enhanced VEGFinduced Erk phosphorylation even at very low VEGF concentrations, between 0.1 to 0.5 ng/mL ( Figure 7A and 7B) . We next examined the influence of rFnIII 9 -10/12-14 on the phosphorylation status of VEGFR-2 activated by a low dose of VEGF. Figure 7C shows that VEGF alone (1 ng/mL) did not significantly induce VEGFR-2 phosphorylation. However, in the presence of rFnIII 9 -10/12-14 , significant VEGFR-2 phosphorylation was observed. Stimulation of cells with VEGF and either rFnIII 9 -10 or rFnIII [12] [13] [14] did not show enhanced VEGFR-2 phosphorylation.
Discussion
Based on our previous studies, we hypothesized that Fn may be a unique biological partner with VEGF: when Fn complexes with VEGF, their coordinated binding to their cognate receptors enhance the specific cellular responses to VEGF. These extracellular events might be an important step in modulating the complex signaling pathways that lead from receptor ligation to cellular response. In this report we have physically mapped a key Fn-binding site for VEGF to the fibronectin C-terminal domain within type III repeats 13 to 14 (the Hep-II domain). Previous studies have established this site as a heparin-binding domain. 24, 25, 30 The Hep-II site is a major syndecan-binding site that plays a role in focal adhesion and stress fiber formation. 32 This report reveals a novel function for the Hep-II region as a site for VEGF binding, as well as a modulator of VEGF activity. Narrowing the binding site further, we observed that a peptide obtained from the N-terminal part of FnIII 14 was most effective at blocking VEGF binding, although other peptides representing heparinbinding sites were also inhibitory. Also, the heparin-binding properties of this Fn domain accounted for a significant portion of VEGF affinity. A heparin-mutant fragment did not bind VEGF, nor did it promote the biological activities of VEGF.
The second important finding from these experiments concerns the mechanism(s) of biological synergism between VEGF and Fn. We found that the VEGF-binding domain of Fn alone was not sufficient to enhance VEGF-mediated cell migration, proliferation, or growth factor signaling, even though it avidly bound VEGF. However, constructs of rFn in which the cell binding and VEGF-binding domains were physically linked dramatically enhanced these cellular responses, even more so than native Fn. rFn fragments containing only the cell-binding domain (FnIII 9 -10 ) did modestly enhance VEGF biological responses. These results may reflect the isolated contribution of the costimulatory signaling pathways that are known to exist between ␣ 5 ␤ 1 and VEGFR-2 downstream to Erk. However, the current data suggest that these cooperative pathways are capable of a much more robust response when their receptors are occupied by a specialized VEGF/Fn complex. The rFnIII 9 -10/12-14 construct 125 I-VEGF/Fn binding assays were performed in the presence of the peptides listed in the Table. A, Results are expressed as the percentage of VEGF binding observed in the absence of competitor (100%) and are the meansϮSEM of 4 to 6 independent experiments performed in triplicate. B, IC 50 (mol/L) was interpolated for each peptide and plotted against the total number of basic residues/peptide. dramatically increased early Erk phosphorylation in response to VEGF, as well as inducing a major late peak in Erk activation at 1.5 hour. Thus, the coordinated extracellular modulation of these ligand/receptor interactions imposes more stringent directions on the intracellular signaling responses to VEGF.
Several lines of evidence suggest that the binding interaction between VEGF and the Hep-II domain are complex. VEGF did not bind to any single isolated immobilized type III repeat, yet VEGF bound to the Fn moieties containing the type III 12-14 repeats in continuity. This suggests that a more complex tertiary structure within the Hep-II domain is necessary for VEGF binding. We observed that the constructs rFnIII 8 -14 and rFnIII 9 -10/12-14 bound more VEGF than rFnIII [12] [13] [14] alone. If FnIII 9 -10 itself has no intrinsic VEGF-binding properties (as we observed), why should the larger construct that includes FIII 9 -10 bind VEGF more avidly? These larger constructs (FnIII 8 -14 and FnIII 9 -10/12-14 ) likely assume a conformation that more optimally displays the VEGF-binding sites. This is supported by the surface plasmon resonance studies, which showed that rFnIII 9 -10/12-14 has a higher affinity for VEGF than native Fn. The bivalent Fn constructs encompassing both the integrin and VEGF-binding sites were also more biologically effective than native Fn. This again may be attributable to conformational differences, or their lack of large portions of the N and C-terminal regions of native Fn, which may play a negative modulatory role on VEGF function.
The heparin-binding properties of the FnIII 12-14 domain are clearly important, as illustrated by the failure of the heparin Figure 5 . A, EC migration to VEGF in the presence of rFn fragments. HUVECs suspended in serum-free MCDB-131 medium containing 0.1% ovalbumin were seeded on to ChemoTx microtiter plates and migration assay performed as described in Materials and Methods. Experiments were performed in triplicate and results expressed as meanϮSEM. The final bar (indicated by 9-10 ϩ 12-14) signifies treatment with a mixture of separate fragments of rFnIII 9 -10 and rFnIII [12] [13] [14] , each at 0.2 mol/L. B, EC proliferation in response to VEGF and rFn fragments. HUVECs (3000 cells/well) in 96-well plates were incubated in MCDB131 medium containing Fn-depleted FBS (0.25%). Cells were incubated with VEGF alone (10 ng/mL), VEGF (V) with native Fn (5 ng/mL), or rFn fragments (0.2 mol/L). In some experiments, heparin (hep) was added at a final concentration of 1 g/mL. Cell growth was determined after 72 hours. Experiments were done in triplicate and results are expressed as meanϮSEM. mutant fragment to bind or modulate VEGF activity. An alternative explanation for the behavior of the heparin mutant protein might be that the mutations altered the conformation of the Fn fragment. Weighing against that possibility are the studies of Mostafavi-Pour, which suggest that these mutations do not seriously alter the conformation of the protein. 26 Also, conformational changes of the mutant (or wild-type recombinant) protein would not explain why peptides selected from these heparin-binding domains successfully competed with rFnIII 9 -10/12-14 for binding VEGF.
However, the peptide competition experiments also suggest that heparin-binding is not the entire VEGF/Fn binding story. The heparin-binding site in III 13 is thought to be the dominant interactive site for heparins, 24 ,25 yet its peptide domain was not the most potent at blocking VEGF binding, nor did its truncated form (the core heparin-binding residues) retain activity. Likewise, comparisons of peptide charge versus inhibitory potency suggest that nonelectrostatic, protein/protein interactions also account for VEGF/Fn binding. The vWf heparin-binding peptide, a highly charged, classical heparin-binding domain, had relatively low affinity for VEGF. This same vWf protein domain has been shown to interfere with cell adhesive strength and chemokinesis, presumably because of its interference with cell syndecan binding to the Hep-II domain of Fn. 33 Thus, this vWf heparin-binding domain may mimic the Fn Hep-II region, from the viewpoint of cell surface syndecans, but not from the perspective of VEGF. Finally, exogenous heparin was not required for rFn-VEGF binding (Figures 2 and 3) . Heparin had the same mild stimulatory effect on the biological activity of rFn/VEGF complexes as its effect on VEGF alone (which is well described).
A number of mechanisms have been suggested for integrin/ growth factor synergism, many emphasizing pathways for intracellular signaling crosstalk. Signaling from ␣ 5 ␤ 1 ligation (and syndecan engagement) can support or reinforce the downstream signaling from VEGFR-2 to Erk. 22 Conversely, VEGFR-2 activation can lead to integrin activation. 21 There exists some controversy as to whether the primary integrin synergizing with VEGF pathways is ␣ 5 ␤ 1 or ␣ v ␤ 3 . 21, 34 This may be attributable to the type of ECM protein the cells are exposed to when stimulated with VEGF. Our previous studies suggest that VEGF/Fn complexes primarily cause a physical association between VEGFR-2 and ␣ 5 ␤ 1 , but not ␣ v ␤ 3 . 22 Moreover, we have also shown that VEGF/Fn complexes, as well as hepatocyte growth factor/Fn complexes, exist and are released from thrombin stimulated degranulating platelets. 22, 35 These observations suggest that platelets may play a role in promoting angiogenesis. Recent studies by Kisucka et al have characterized the role platelets play in modulating angiogenesis in vivo. 36 We also observed that blockade of ␣ 5 ␤ 1 profoundly inhibits VEGF-mediated migration and differentiation of endothelial progenitor cells. 22, 23 These findings support the view espoused by Hynes and colleagues that ␣ 5 ␤ 1 is a pivotal integrin for vascular development. 6, 37, 38 The current experiments suggest that the mechanism of Fninduced enhancement of VEGF activity arises from both the formation of an extracellular complex interacting with the cell surface receptors and the resulting promotion of costimulatory signaling from integrin and VEGF receptor. Simple engagement of integrin and growth factor receptors by free, independent ligands does not induce the same quality or quantity of signaling, especially the late sustained Erk phosphorylation. In support of our hypothesis, recent studies of a parallel system demonstrated that binding of basic fibroblast growth factor to fibrinogen is required for the enhancement of basic fibroblast growth factor induced angiogenesis. 39 More work will be needed to identify the interactive sites within VEGF and to define the role of the CS-1 domain of Fn also remains to be elucidated in this context. Further understanding of the structure/function relationship of these synergisms should permit the development and optimization of Fn-derived constructs that specifically amplify (or inhibit) the biological actions of VEGF. 
